Ajanta Pharma Limited (BOM:532331)
India · Delayed Price · Currency is INR | Market Cap | 359.66B +12.4% |
| Revenue (ttm) | 52.02B +14.8% |
| Net Income | 10.15B +13.0% |
| EPS | 81.21 +13.5% |
| Shares Out | n/a |
| PE Ratio | 35.45 |
| Forward PE | 29.95 |
| Dividend | 28.00 (0.96%) |
| Ex-Dividend Date | Nov 10, 2025 |
| Volume | 1,583 |
| Average Volume | 15,674 |
| Open | 2,900.00 |
| Previous Close | 2,862.50 |
| Day's Range | 2,867.60 - 2,951.40 |
| 52-Week Range | 2,022.05 - 3,158.20 |
| Beta | n/a |
| RSI | 45.98 |
| Earnings Date | Apr 30, 2026 |
About Ajanta Pharma
Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company that develops, manufactures, and markets specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, and pain management. The company operates in India, Africa, Asia, the United States, and intern... [Read more]
Financial Performance
In fiscal year 2025, Ajanta Pharma's revenue was 46.48 billion, an increase of 10.44% compared to the previous year's 42.09 billion. Earnings were 9.20 billion, an increase of 12.77%.
Financial StatementsNews
Pharma sector stocks today, March 23: Alembic Pharma down 2.24%, Ajanta Pharma falls 1.85%, Glenmark Pharma falls 1.98%
The pharmaceutical sector in India experienced a downturn on March 23, 2026, as reflected in early morning trading data from BSE and NSE around 9:29-9:30 AM IST. Most listed pharma…
Pharma sector stocks today, March 17: Emcure Pharma surge 2.42%, Ajanta Pharma up 2.14%, Strides Pharma down 2.22%
The Indian pharmaceutical sector showed mixed performance on March 17, 2026, during early trading hours. The data reflects prices as of approximately 9:34 AM IST, with the S&P BSE HEALTHCARE…
Pharma sector stocks today, March 13: Laurus Labs down 2.56%, Ajanta Pharma falls 1.88%, Granules India drops 2.14%
The Indian pharmaceutical sector showed a downward trend in early trading on March 13, 2026, aligning with broader market weakness. The S&P BSE Healthcare Index stood at 43,441.0, down 0.6%…
Pharma sector stocks down today, March 2: Morepen Lab falls 3.24%, Ajanta Pharma drops 2.32%, Natco Pharma down 2.26%
The Indian pharmaceutical sector experienced a sharp decline on March 2, 2026, with many stocks trading lower in early sessions....
Ajanta Pharma Ltd (BOM:532331) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and ...
Ajanta Pharma Ltd (BOM:532331) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion Plans
Q3 2026 Ajanta Pharma Ltd Earnings Call Transcript
Q3 2026 Ajanta Pharma Ltd Earnings Call Transcript
Pharma sector stocks today, Jan 30: Aurobindo Pharma jumps 3%, Ajanta Pharma up 2%, Natco Pharma rises 2%
The Indian pharma sector stocks showed mixed performance on January 30, 2026, as of approximately 10:31 AM IST. The sector...
India’s Ajanta Pharma eyes Irish manufacturing base
Indian speciality pharmaceutical firm Ajanta Pharma is understood to be eyeing a manufacturing operation in Ireland.
Ajanta Pharma shares jump over 4% after signing in-licensing agreement with Biocon
Shares of Ajanta Pharma Ltd. moved over 4% higher in early trade after the company announced a strategic in-licensing agreement...
Biocon signs out-licensing deal with Ajanta Pharma to market Semaglutide in overseas markets
Biocon Limited has announced the signing of an out-licensing agreement with Ajanta Pharma Ltd for the marketing of its vertically...
Bharti Airtel, Titan & more: Top stocks on brokers' radar today
Analysts are bullish on Bharti Airtel and Titan, citing strong quarterly results and positive outlooks. Ambuja Cements shows robust EBITDA, while Ajanta Pharma beats estimates with strong internationa...
Ajanta Pharma Ltd (BOM:532331) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amidst ...
Ajanta Pharma Ltd (BOM:532331) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amidst Forex Challenges
Q2 2026 Ajanta Pharma Ltd Earnings Call Transcript
Q2 2026 Ajanta Pharma Ltd Earnings Call Transcript
Ajanta Pharma to consider interim dividend for FY26 at November 3 board meeting; record date set for November 10
Ajanta Pharma Limited has informed the exchanges that its Board of Directors will meet on Monday, November 3, 2025, to...
Top stocks to watch today, August 21: Godrej Properties, RailTel, Ajanta Pharma, India Cements and more
Several Indian companies are set to attract attention in today’s trading session following key corporate developments and announcements. Here’s a roundup of the notable stocks and the latest news driv...
Ajanta Pharma confirms IT raid reports, says business operations remain unaffected
Shares of Ajanta Pharma Ltd. declined nearly 3% on Tuesday, August 19, after reports surfaced of Income Tax department raids at the company’s premises. Business Upturn first reported the development, ...
Ajanta Pharma shares fall 3% after reports of Income Tax raids
Shares of Ajanta Pharma slipped in trade on Tuesday after news reports suggested that the Income Tax department is conducting raids at the company’s premises. According to Zee Business, search operati...
Ajanta Pharma in focus as Income Tax raid underway at company premises
Shares of Ajanta Pharma will be in focus after reports emerged that the Income Tax department has conducted raids at the company’s premises, according to Zee Business. Details of the search operations...
Top stocks to buy today: Stock recommendations for July 31, 2025 - check list
Top stock market recommendations: Nuvama Professional Clients Group's Aakash K Hindocha recommends buying Jindal Steel, Ajanta Pharma, and Godrej Agrovet. Hindocha anticipates range-bound trading for ...
Ajanta Pharma Q4 Results: Net profit grows 11% YoY to Rs 225 crore, EBITDA Margin at 25%
Ajanta Pharma Ltd. reported an 11% year-on-year increase in profit after tax (PAT) for the quarter ended March 31, 2025, at ₹225 crore, compared to ₹203 crore in the same period last year.
Stocks to buy today on brokerages’ call: IndiGo, Ajanta Pharma, TBO, HDFC Bank, Vodafone Idea among top picks – Check investment target
Several brokerage firms have issued fresh calls on select Indian stocks, highlighting investment opportunities and risks across sectors. While these are views expressed by the respective brokerage hou...
Jefferies initiates Buy on Ajanta Pharma, sees 11% upside due to strong presence in branded generics markets
Jefferies has initiated coverage on Ajanta Pharma with a ‘Buy’ call, projecting an upside of 11% from the current market price of ₹2,574.00 (as of April 11, 2025). The brokerage has set a target price...
Stocks to watch today: Interglobe Aviation, Ajanta Pharma, HDFC Bank, Vodafone Idea, Hindalco, TBO, L&T in focus on brokerage reports
A host of stocks are likely to remain in the spotlight today as several brokerages have issued fresh commentary and call actions, including upgrades, initiations, and revised target prices. Among the ...
Ajanta Pharma Q3FY25 results: Revenue rises 4% YoY to Rs 1,146 crore, PAT Up 11% to Rs 233 crore
According to IQVIA MAT December 2024 data, Ajanta Pharma’s India growth was 11%, outpacing the Indian Pharmaceutical Market (IPM) growth of 8%.
Pharma Stocks: Cipla down nearly 2%, Ajanta Pharma down 1.45%, Abbott India up 1.27%
The Nifty Pharma index was trading 0.25% lower at 22,389.10 during today’s session, as losses in Cipla, Biocon, and Aurobindo Pharma weighed on the sector, despite gains in Abbott India and Ajanta Pha...